165 related articles for article (PubMed ID: 38111589)
21. Changes in CD4+CD25+FoxP3+ Regulatory T Cells and Serum Cytokines in Sublingual and Subcutaneous Immunotherapy in Allergic Rhinitis with or without Asthma.
Xian M; Feng M; Dong Y; Wei N; Su Q; Li J
Int Arch Allergy Immunol; 2020; 181(1):71-80. PubMed ID: 31722337
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
[TBL] [Abstract][Full Text] [Related]
23. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.
Mosbech H; Canonica GW; Backer V; de Blay F; Klimek L; Broge L; Ljørring C
Ann Allergy Asthma Immunol; 2015 Feb; 114(2):134-40. PubMed ID: 25624131
[TBL] [Abstract][Full Text] [Related]
24. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
[TBL] [Abstract][Full Text] [Related]
25. House dust mite sublingual immunotherapy in allergic rhinitis.
Cho SW; Han DH; Kim JW; Kim DY; Rhee CS
Immunotherapy; 2018 Jun; 10(7):567-578. PubMed ID: 29562802
[TBL] [Abstract][Full Text] [Related]
26. SQ house dust mite sublingual immunotherapy for the treatment of adults with house dust mite-induced allergic rhinitis.
Meteran H; Backer V
Expert Rev Clin Immunol; 2019 Nov; 15(11):1127-1133. PubMed ID: 31584839
[No Abstract] [Full Text] [Related]
27. House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma.
Richards JR; Stumpf JL
Ann Pharmacother; 2018 Oct; 52(10):1019-1030. PubMed ID: 29642713
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
[TBL] [Abstract][Full Text] [Related]
29. Investigating the T regulatory cells and Sirtuin-I serum level in immunotherapy treated house dust mite allergic asthma patients.
A Mohamed R; Fakhr AE; A Baioumy S
J Asthma; 2024 Apr; 61(4):348-359. PubMed ID: 37855683
[TBL] [Abstract][Full Text] [Related]
30. Sublingual Immunotherapy for Asthmatic Children Sensitized to House Dust Mite: A Meta-Analysis.
Liao W; Hu Q; Shen LL; Hu Y; Tao HF; Li HF; Fan WT
Medicine (Baltimore); 2015 Jun; 94(24):e701. PubMed ID: 26091451
[TBL] [Abstract][Full Text] [Related]
31. Clinical and cytokine responses to house dust mite sublingual immunotherapy.
Potter PC; Baker S; Fenemore B; Nurse B
Ann Allergy Asthma Immunol; 2015 Apr; 114(4):327-34. PubMed ID: 25661658
[TBL] [Abstract][Full Text] [Related]
32. House dust mite sublingual immunotherapy tablet safety in adolescents with allergic rhinoconjunctivitis: Worldwide clinical trial results.
Horn A; Bernstein DI; Okubo K; Dalgaard T; Hels O; Sørensen HF; Henriksen M; Azuma R; Mikler J; Nolte H
Ann Allergy Asthma Immunol; 2023 Jun; 130(6):797-804.e2. PubMed ID: 36924936
[TBL] [Abstract][Full Text] [Related]
33. Correlation between sensitization to house dust mite major allergens, age, and symptoms in Japanese house dust mite allergic subjects.
Hasegawa A; Utsumi D; Lund K; Okano M; Ohashi-Doi K; Okubo K
Int Immunopharmacol; 2022 Jun; 107():108640. PubMed ID: 35217338
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma.
Canonica GW; Virchow JC; Zieglmayer P; Ljørring C; Smith IM; Mosbech H
Expert Rev Clin Immunol; 2016 Aug; 12(8):805-15. PubMed ID: 27322777
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of HDM SLIT Tablet in Japanese Adults with Allergic Asthma.
Tanaka A; Tohda Y; Okamiya K; Azuma R; Terada I; Adachi M
J Allergy Clin Immunol Pract; 2020 Feb; 8(2):710-720.e14. PubMed ID: 31541768
[TBL] [Abstract][Full Text] [Related]
36. Serum Soluble ST2 Correlated with Symptom Severity and Clinical Response of Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis Patients.
Zhu K; Xia C; Chen J; Yu C; Gao T; Yan J; Shao N; Zhu P; Sun B; Ren X; Zhang Y
Mediators Inflamm; 2021; 2021():5576596. PubMed ID: 34194284
[TBL] [Abstract][Full Text] [Related]
37. House Dust Mite-Specific Sublingual Immunotherapy Prevents the Development of Allergic Inflammation in a Mouse Model of Experimental Asthma.
Hagner S; Rask C; Brimnes J; Andersen PS; Raifer H; Renz H; Garn H
Int Arch Allergy Immunol; 2016; 170(1):22-34. PubMed ID: 27287860
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of house dust mite allergen immunotherapy in children with allergic asthma.
Farraia M; Paciência I; Castro Mendes F; Cavaleiro Rufo J; H Shamji M; Agache I; Moreira A
Allergy; 2022 Sep; 77(9):2688-2698. PubMed ID: 35451128
[TBL] [Abstract][Full Text] [Related]
39. Comparison of rush-subcutaneous and sublingual immunotherapy with house dust mite extract for pediatric allergic rhinitis: A prospective cohort study.
Hamada M; Saeki K; Tanaka I
Allergol Int; 2023 Oct; 72(4):573-579. PubMed ID: 36918306
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of House Dust Mite Sublingual Immunotherapy in Patients with Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.
Langer SS; Cardili RN; Melo JML; Ferriani MPL; Moreno AS; Dias MM; Bueno-Filho R; Pocente RHC; Roxo-Junior P; Silva J; Valera FCP; Coelho EB; Galvão CES; Carmona F; Aragon DC; Arruda LK
J Allergy Clin Immunol Pract; 2022 Feb; 10(2):539-549.e7. PubMed ID: 34767999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
